PSTV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PSTV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Plus Therapeutics's Other Financing for the three months ended in Sep. 2024 was $0.00 Mil.
Plus Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.47 Mil.
The historical data trend for Plus Therapeutics's Other Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Other Financing | Get a 7-Day Free Trial | 0.49 | 1.10 | 2.02 | -0.77 | -0.35 |
Plus Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Other Financing | Get a 7-Day Free Trial | - | -0.47 | - | - | - |
Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges
Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Plus Therapeutics's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard J Hawkins | director | 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125 |
Greg Petersen | director | 3100 MAIN STREET, SUITE 900, HOUSTON TX 77002 |
Howard Clowes | director | 217 DWIGHT ROAD, BURLINGAME CA 94010 |
Marc H Hedrick | officer: President | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Sims Andrew John Hugh Macintyre | officer: Chief Financial Officer | 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756 |
Robert P Lenk | director | LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060 |
Norman D. Lafrance | officer: CHIEF MEDICAL OFFICER | MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142 |
Es-johansson An Van | director | 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736 |
Ag Postfinance | 10 percent owner | MINGERSTRASSE 20, BERN V8 3030 |
Bank Sa Swissquote | 10 percent owner | CHEMIN DE LA CRETAUX 33, GLAND V8 1196 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Ron Martell | director | PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
Mark Marino | officer: Chief Medical Officer | C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
John David Harris | officer: VP and GM of Cell Therapy | 3020 CALLAN ROAD, SAN DIEGO CA 92121 |
Gail K Naughton | director | C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
From GuruFocus
By Marketwired • 11-25-2024
By Marketwired • 05-17-2024
By GuruFocus Research • 05-16-2024
By GlobeNewswire • 05-08-2024
By Marketwired • 09-04-2024
By Marketwired • 10-29-2024
By Marketwired • 07-25-2024
By Marketwired • 09-18-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.